Table 1.
Case | Age (y)/Sex | FPL | Hans | NS | Gene | Mutation | VAF, % |
---|---|---|---|---|---|---|---|
1 | 59 F | ABC | ABC | ABC | |||
2 | 57 M | GCB | GCB | GCB | |||
3 | 52 M | ABC | ABC | ABC | MYC | p.Gln52del | 10.5 |
4 | 69 M | ABC | ABC | ABC | |||
5 | 86 F | GCB | GCB | GCB | TNFRSF13B | p.Cys104Tyr | 75.0 |
BRAF | p.Lys601Glu | 48.0 | |||||
6 | 60 M | ABC | ABC | ABC | MYD88 | p.Val217Phe | 30.1 |
7 | 53 M | GCB | GCB | GCB | BLNK | p.Glu60Lys | 38.1 |
8 | 75 M | GCB | GCB | GCB | |||
9 | 76 F | ABC | ABC | ABC | TCF3 | p.Gly362Asp | 59.5 |
ALK | p.Thr1026Pro | 22.0 | |||||
10 | 52 F | ABC | ABC | ABC | XPO1 | p.Glu571Lys | 31.8 |
11 | 31 M | GCB | GCB | GCB | MYC | p.Pro233Thr | 89.7 |
12 | 83 M | GCB | GCB | GCB | |||
13 | 34 M | GCB | GCB | GCB | |||
14 | 44 F | ABC | ABC | ABC | KRAS | p.Gly12Cys | 23.1 |
AICDA | p.Arg25His | 29.1 | |||||
15 | 39 F | GCB | GCB | GCB | |||
16 | 43 M | GCB | GCB | GCB | MYC | p.Asp2His | 51.1 |
SYNE1 | p.Leu3057Val | 52.5 | |||||
17 | 60 M | ABC | ABC | ABC | |||
18 | 27 F | GCB | GCB | GCB | XPO1 | p.Glu571Lys | 36.0 |
19 | 62 M | ABC | ABC | ABC | MUC1 | p.Arg99Cys | 49.1 |
20 | 74 F | GCB | GCB | GCB | BLNK | p.Gly30Arg | 48.2 |
21 | 39 M | GCB | GCB | GCB | |||
22 | 62 M | GCB | GCB | GCB | PIM1 | p.Glu170Asp | 41.5 |
ALK | p.Thr1026Pro | 37.1 | |||||
23 | 84 F | GCB | GCB | GCB | |||
24 | 61 M | ABC | ABC | ABC | BCL3 | p.Ala68Val | 48.8 |
25 | 70 M | GCB | GCB | GCB | BCL2 | p.Pro233Thr | 89.7 |
26 | 71 M | ABC | ABC | ABC | PIM1 | p.Ala113Thr | 74.2 |
PIM1 | p.Gly141Asp | 73.8 | |||||
PIM1 | p.Gly119Asp | 47.8 | |||||
PIM1 | p.Asn269Ser | 18.5 | |||||
MYD88 | p.Leu265Pro | 33.8 | |||||
27 | 61 F | GCB | GCB | GCB | PDCD1LG2 | p.Glu11AsnfsTer7 | 66.7 |
28 | 35 M | GCB | ABC | GCB | |||
29 | 65 F | GCB | ABC | GCB | ALK | p.Thr1026Pro | 28.6 |
30 | 74 M | GCB | ABC | GCB | ALK | p.Thr1026Pro | 25.8 |
31 | 72 F | UNC | ABC | UNC | TCF3 | p.Gly362Asp | 57.4 |
KMT2A | p.Leu3614Pro | 52.9 | |||||
32 | 62 M | GCB | ABC | GCB | BCL2 | p.Ser87Arg | 25.2 |
33 | 21 M | GCB | ABC | GCB | |||
34 | 66 M | UNC | ABC | UNC | |||
35 | 84 F | GCB | ABC | ABC | |||
36 | 42 M | UNC | ABC | ABC | |||
37 | 31 M | GCB | ABC | ABC | |||
38 | 71 M | ABC | ABC | GCB | |||
39 | 59 M | GCB | ABC | ABC | ETV6 | p.Lys11Asn | 34.8 |
MYD88 | p.Leu265Pro | 51.9 | |||||
ALK1 | p.Thr1026Pro | 53.3 | |||||
40 | 66 M | GCB | GCB | UNC | BMP7 | p.Pro106Ala | 92.9 |
PIM1 | p.Val90Leu | 51.8 | |||||
PIM1 | p.Val90Ile | 41.0 | |||||
41 | 83 F | ABC | ABC | GCB | LRMP | p.Ile102Val | 46.6 |
ABC, activated B-cell subtype; FPL, Archer FusionPlex Lymphoma assay; GCB, germinal center B-cell subtype; NS, NanoString; UNC, unclassified; VAF, variant allele fraction.
aFor the purposes of comparison between methods, cases classified as ABC and UNC categories by the FusionPlex Lymphoma panel and/or NS were considered non-GCB.